4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease

Safety, Tolerability and Pharmacokinetics of 3 Dose Regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo Controlled, Parallel Group Phase IIa Study in Patients With Mild to Moderate Alzheimer's Disease During 4 Weeks of Treatment

The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.

Inclusion Criteria:

• history of progressive worsening of memory and other cognitive functions for at least 12 months
• treatment with stable dose of donepezil (10 mg) for at least 3 months
• the patient should have an appropriate caregiver, who is required for all study visits

Exclusion Criteria:

• history of allergy/hypersensitivity reactions
• significant neurological disease or dementia other than Alzheimer's disease
• myocardial infarction or acute coronary syndrome within the last year